• 20066 Citations
1988 …2024

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research Interests

Dr. Hussain's research is focused on the development of novel therapeutics integrating scientific advances into clinical trials in prostate and bladder cancer.

Dr. Hussain is a GU medical oncologist with a focus on prostate and bladder cancer.

Maha Hussain, MD, FACP, FASCO, is the Genevieve Teuton Professor of Medicine in the Division of Hematology Oncology, Department of Medicine, and the Deputy Director at the Robert H. Lurie Comprehensive Cancer Center of the Northwestern University Feinberg School of Medicine. She is a practicing oncologist, internationally renowned expert and clinical researcher in genitourinary oncology particularly prostate and bladder cancer. Her clinical research has contributed to impacting the standards of care for patients with metastatic hormone sensitive and castration resistant prostate cancer. Prior to joining the Northwestern University faculty Dr. Hussain has served in many scientific and leadership roles at the University of Michigan Comprehensive Cancer Center including Associate Director for Clinical Research and Co-Leader of the Prostate Cancer/Genitourinary Oncology Program, as well as the Associate Chief for Clinical Research in the Division of Hematology/Oncology. At the national level Dr. Hussain has served in a variety of scientific leadership roles, including the Co-Chair of the SWOG Prostate Cancer Subcommittee (1994-2012), member (2009-2014) and Chair (2013-2014) of the Integration Panel of the U.S. Army Medical Research and Materiel Command Prostate Cancer Research Program, and was a member (2004-2008) and Chair (2007-2008) of the U.S. Food and Drug Administration Oncology Drug Advisory Committee. Dr. Hussain was a member of the NCI-Cancer Biomarker Study Section and the NCI’s Prostate cancer task force. She currently serves as an EAB member for several NCI-designated cancer centers and the UCLA Prostate Cancer SPORE. Since joining the American Society of Clinical Oncology in 1990, Dr. Hussain has served on numerous committees and boards, including the Scientific Program, Cancer Education, International Affairs, and Cancer Communications committees. In addition, she chaired the Cancer Education Committee (2008-2009), the Genitourinary Cancers Symposium Program Committee (2010-2011) and the Genitourinary Cancers Symposium Steering Committee (2013-2014) and was Associate Editor for Cancer.Net. She currently serves on the Clinical Practice Guidelines Committee and is an elected member of the ASCO Board of Directors. Dr. Hussain is the author of more than 240 scholarly articles and book chapters. She serves/has served on the editorial boards for several national and international specialty publications. She has been invited to give hundreds of lectures on her work in the United States and many countries around the world. Dr. Hussain has received many honors, including the University of Michigan Comprehensive Cancer Center Leadership Award (2007), the University of Michigan Medical School League Of Research Excellence (2011), and the 2012 Clinical & Health Services Research Award. She was elected as a Fellow of ASCO (2010). She has been named for many years in America’s Top Doctors” and “America´s Top Doctors for Cancer. In 2015 she was named one of OncLive’s Giants of Cancer Care and in 2017 she was named Castle Connolly Exceptional Women in Medicine.

Training Experience

1983Internship, Wayne State University
1986Residency, Wayne State University School of Medicine, Detroit, Michigan
1989Fellowship, Wayne State University School of Medicine, Detroit, Michigan

Education/Academic qualification

MBChB, Baghdad University College of Medicine, Baghdad, Iraq

… → 1980

Fingerprint Dive into the research topics where Maha Hussain is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 2 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants

  • ETCTN Participation

    Hussain, M.

    National Cancer Institute

    8/10/187/31/23

    Project: Research project

  • Research Output

    Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public Workshop

    Weinstock, C., Suzman, D., Kluetz, P., Baxley, J., Viviano, C., Ibrahim, A., Jarow, J., Sridhara, R., Liu, K., Carroll, P., Eggener, S., Hu, J. C., Hussain, M., King, M., Klein, E., Kungel, T., Makarov, D., Pinto, P. A., Rini, B., Roach, M. & 6 others, Sandler, H., Schlegel, P. N., Song, D., Goldberg, K., Pazdur, R. & Beaver, J. A., Jan 1 2020, In : The Journal of urology. 203, 1, p. 115-119 5 p.

    Research output: Contribution to journalArticle

  • 1 Scopus citations

    Efficacy and Effect of Cabozantinib on Bone Metastases in Treatment-naive Castration-resistant Prostate Cancer

    Smith, D. C., Daignault-Newton, S., Grivas, P., Reichert, Z. R., Hussain, M., Cooney, K. A., Caram, M., Alva, A., Jacobson, J., Yablon, C., Mehra, R., Escara-Wilke, J., Shelley, G. & Keller, E. T., Jan 1 2020, (Accepted/In press) In : Clinical Genitourinary Cancer.

    Research output: Contribution to journalArticle

  • Relugolix: Early Promise for a Novel Oral Androgen Deprivation Therapy with Radiation Therapy for Prostate Cancer

    Sachdev, S., Zhang, H. & Hussain, M., Jan 1 2020, (Accepted/In press) In : European urology.

    Research output: Contribution to journalEditorial

    Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer

    Wong, R. L., Duong, M. T., Tangen, C. M., Agarwal, N., Cheng, H. H., Vogelzang, N. J., Hussain, M., Thompson, I. M., Quinn, D. I. & Yu, E. Y., Jan 1 2020, (Accepted/In press) In : Prostate Cancer and Prostatic Diseases.

    Research output: Contribution to journalArticle